Oncology

Oropharyngeal Carcinoma: Better Outlook From Human Papilloma Virus-Directed Therapies— Different Patient Characteristics, New Therapeutic Opportunities

Marshall Posner

Marshall Posner MD

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Marshall Posner MD from the Dana-Farber Cancer Institute in Boston about the increased prevalence of oropharygeal cancers which are related to HPV infection. These tumors may be less aggressive than cancers testing negative for HPV, and have proved more responsive to the most effective modern therapies which use docetaxel along with cisplatin and fluorouracil for induction prior to standard chemo-radiotherapy. He discusses the need for biological agents and drugs directed against the human papilloma virus which is essential for maintaining malignant phenotype and the urgency of vaccinating 12 to 24 year olds to reduce the pool of infection.

Similar Interviews

  • Latest on Human Papilloma Virus Vaccine for Cervical Cancer
  • John Schiller John Schiller, National Cancer Institute, Bethesda The human papilloma virus vaccine, which is currently being tested in the prevention of

  • Eight Blood Pressure Genes Bring Promise For Drug Design
  • [caption id="attachment_844" align="alignnone" width="120" caption="Mark Caulfield"][/caption]Eight human genes have been recognised as modulating blood pressure by a team from London,

  • Bluetongue Disease Of Sheep: Two New Vaccines On The Way
  • [caption id="attachment_1076" align="alignnone" width="120" caption="Polly Roy"][/caption] Professor Polly Roy discusses her team's new vaccines for bluetongue: a lethal midge-borne disease

    Post a comment